Zalutumumab in Head and Neck Cancer
NCT00093041 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2023-06-28
Summary
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
Conditions
- Head and Neck Neoplasms
Interventions
- DRUG
-
Zalutumumab
Weekly infusion
Sponsors & Collaborators
-
Genmab
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-12-01
- Primary Completion
- 2005-01-12
- Completion
- 2005-01-12
- FDA Drug
- Yes
Countries
- Denmark
- Sweden
Study Locations
More Related Trials
-
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
NCT00015964 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00507767 ·Status: COMPLETED ·Phase: PHASE2
-
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
NCT00496652 ·Status: COMPLETED ·Phase: PHASE3
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label, Phase I ZD6474 Head and Neck Cancer Study
NCT00450138 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
NCT04854499 ·Status: TERMINATED ·Phase: PHASE2
-
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
NCT05423197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03522584 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT02538510 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03433027 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT06912087 ·Status: RECRUITING ·Phase: PHASE1
-
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
NCT04326257 ·Status: COMPLETED ·Phase: PHASE2
-
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00458978 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
NCT02262741 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
NCT00358956 ·Status: COMPLETED ·Phase: PHASE2
-
Chemo-embolization for Head and Neck Cancer
NCT04595981 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
NCT02358031 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
NCT03132038 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Electrochemotherapy on Head and Neck Cancer
NCT02549742 ·Status: UNKNOWN ·Phase: PHASE2
-
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
NCT05317000 ·Status: RECRUITING ·Phase: PHASE2
-
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00095628 ·Status: COMPLETED ·Phase: PHASE2